AMAL vs SRPT · P/E 9.8, rev $226.5M vs rev $1.13B
Amalgamated Bank (AMAL) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
Amalgamated Bank (AMAL) is a banks - regional company listed on US.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Latest reported AMAL revenue for 2026-06-30 was $226.5M. Net income was $60.0M. AMAL currently screens at market cap $1.02B and trailing P/E 9.8.
Latest reported SRPT revenue for 2026-06-30 was $1.13B. Net income was $326.1M. Revenue was up 54.9% from 2026-03-31 to 2026-06-30. SRPT currently screens at market cap $2.34B.
AMAL currently screens at market cap $1.02B and trailing P/E 9.8. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the AMAL and SRPT stock pages for the full models.
Not investment advice.